MedPath

Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy

Not Applicable
Completed
Conditions
Pancreatic Cystic Lesions
Pancreatic Cancer
Chronic Pancreatitis
Pancreatic Neuroendocrine Tumors
Pancreatic Pseudocysts
Interventions
Procedure: Stapling closure of the pancreatic stump
Procedure: Roux-en-Y anastomosis of the pancreatic stump
Registration Number
NCT01384617
Lead Sponsor
Wakayama Medical University
Brief Summary

The objective is to clarify Roux-en-Y anastomosis of the pancreatic stump decreases pancreatic fistula following distal pancreatectomy, compared with stapling closure of the pancreatic stump.

Detailed Description

The objective of this study was to clarify Roux-en-Y anastomosis of the pancreatic stump prevents pancreatic fistula after distal pancreatectomy (DP) compared to stapling closure of the pancreatic stump in a prospective randomized controlled trail.

Various methods and technique for treating surgical stump of the remnant pancreas have been reported to reduce pancreatic fistula after DP. However, appropriate surgical stump closure after DP is still controversial.

The primary endpoint in this trial was defined as the incidence of pancreatic fistula .

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
136
Inclusion Criteria
  1. disease of pancreatic body and tail
  2. PS (ECOG Performance Status Scale):0-1
  3. Age: 20 years or older
  4. distant metastases are not diagnosed preoperatively. Eligible for this clinical study when only distal pancreatectomy contributes to the favorable prognosis even if patients with pancreatic neuroendocrine cancer have the liver metastasis.
  5. Adequate organ functions filled the following criteria within two weeks from enrollment:

1.White blood cell: >3,500/mm3 or <12,000/mm3 2.Neutrophilic leukocyte >2,000/mm3 3.Platelet>100,000/mm3 4.Hemoglobin > 9.0g/dL 5.Total bilirubin <2.0mg/dL 6.AST and ALT<150IU/L 7.Creatinine <1.5mg/dL 6)Patients who can provide written informed consent

Exclusion Criteria
  1. Patients with severe liver cirrhosis or active hepatitis
  2. Patients with respiratory illness that requires oxygen administration
  3. .Patients with chronic renal failure requiring dialysis
  4. Patients with active duplicative malignant disease affecting adverse event
  5. Others, patients who are unfit for the study as determined by the attending physician

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Stapling closure of the pancreatic stumpStapling closure of the pancreatic stumpEchelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
Roux-en-Y anastomosis of the pancreatic stumpRoux-en-Y anastomosis of the pancreatic stumpend-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
Primary Outcome Measures
NameTimeMethod
Incidence of pancreatic fistula defined by ISGPF classification3 month after operation
Secondary Outcome Measures
NameTimeMethod
postoperative hospital stay3 month after operation
Incidence of pancreatic fistula grade B/C stratified based on thickness of pancreas parenchyma3 months after oepration
morbidity3 months after opeartion
nutritional status2 years after opeartion
Incidence of pancreatic fistula gradeB/C defined by ISGPF classification3 months after oepration
quality of life2 years after operation
new onset or worsening diabetes2 years after opeartion
mortality3 months after operation
Incidence of pancreatic fistula stratified based on thickness of pancreas parenchyma3 months after operation

Trial Locations

Locations (1)

Second Department of Surgery, Wakayama Medical University, School of Medicine

🇯🇵

Wakayama, Japan

© Copyright 2025. All Rights Reserved by MedPath